Loading…
GYRE Therapeutics Inc
GYRE Therapeutics Inc (GYRE) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in San Diego, United States and has 625 employees. The company is worth $644.69M. Revenue was $116.59M in fiscal 2025, up 10.2% from the year before. Net income was $9.88M. The share price is 33.5% below its 52-week high of $9.14. One of the 38 superinvestors we track held it at the end of Q2 2026: Israel Englander (Millennium Management), at $121.84K. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -66.2% over 5Y.
today you would have $757.05▼ -24.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $7.06 | $12.10 | $25.69 | $7.95 | $13.65 | $94.65 | $102.15 | $118.35 | $204.60 | $146.25 | $704.25 | $4,142.25 | $6,536.25 | $6,898.50 | $8,772.75 | $41,737.50 | $32,917.50 | |
| P/E |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| KIDSOrthopediatrics Corp | $24.71 | — | 1.9x | 0.00% | -11.36% | $645.17M |
| ABUSArbutus Biopharma Corp | $4.22 | 5.3x | 3.2x | 0.00% | 89.58% | $646.82M |
| PACBPacific Biosciences of California Inc | $2.06 | — | — | 0.00% | -929.32% | $640.31M |
| DNAGinkgo Bioworks Holdings, Inc. |
| — |
| 353.0x |
| 242.0x |
| — |
| 265.0x |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| 73.6x |
| — |
| P/S | 10.1x | 5.9x | 10.7x | 19.3x | 0.2x | 3.9x | 9.4x | — | 15740.6x | 159.4x | — | — | 323.2x | 38.6x | 2.5x | 1.9x | 8.9x | 21.4x |
| P/B | 1.2x | 6.5x | 17.9x | — | 0.5x | 0.7x | 2.6x | 1.2x | 0.8x | 5.3x | 0.6x | 1.1x | — | — | — | 1.1x | 8.3x | 7.8x |
| EPS | $0.02 | $0.05 | -$1.41 | $0.03 | -$43.05 | -$43.95 | -$69.00 | -$40.20 | -$111.75 | -$326.25 | -$749.85 | -$4,047.75 | -$6,140.25 | -$330.75 | -$425.25 | $567.00 | -$2,425.50 |
| Dividend yield | 127.25% | — | — | 14.01% | 269.81% | — | — | — | — | — | — | 127.25% | — | — | — | — | — | — |
| Payout | — | — | — | — | 71500.00% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Profit margin | -116.29% | 8.47% | 16.92% | -75.35% | 4.22% | -1198.32% | -268.48% | — | -500916.67% | -2117.98% | — | — | -2404.73% | -274.62% | -12.09% | -8.74% | 12.72% | -157.23% |
| ROE | -46.98% | 9.32% | 28.27% | — | 10.15% | -214.01% | -73.93% | -80.75% | -25.06% | -70.06% | -105.44% | -46.98% | — | — | — | -4.89% | 11.87% | -57.11% |
Median of the years shown; P/E years above 200x are left out.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
1 methods answered, across 1 families.
Room for errors in the reported numbers.
-60.4% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| $9.71 |
| — |
| 1.5x |
| 0.00% |
| -59.94% |
| $653.87M |
| FDMT4D Molecular Therapeutics, Inc. | $11.85 | — | 1.6x | 0.00% | -43.25% | $654.64M |
| STLNStarling Oncology, Inc. | $6.43 | — | — | 0.00% | — | $655.32M |